G20
SOUTH AFRICA 2025

Solidarity
Equality
Sustainability

ADDRESSING GAPS AND SEIZING OPPORTUNITIES: HOW INCUBATORS AND ACCELERATORS DRIVE AFRICA'S BIOECONOMY

Dheepak Maharajh
CEO UVU Bio

25 February 2025

G20
SOUTH AFRICA 2025

Solidarity
Equality
Sustainability

Opportunities in Africa's Bioeconomy

Harnessing Potential

Potential of Africa's Incubation and Acceleration Ecosystem



Unlocking Africa's Rich Biodiversity

- Unparalleled biodiversity and Indigenous knowledge
- Unique opportunities for developing bio-based industries
  - Pharmaceuticals,
  - agriculture,
  - environmental sustainability

Opportunity for Sustainable Innovation

Ecosystem presents opportunities (and a market) for developing sustainable bioeconomy solutions, contributing to environmental sustainability



Demographic Dividend:

- Africa has the world's youngest population
- This creates a vibrant pool of talent, energy, and creativity, making it an ideal region for incubators targeting youth entrepreneurship

Leapfrogging Technology:

Unique ability to leapfrog traditional technologies, especially in mobile and fintech. The continent is home to some of the most innovative solutions for mobile payments, e-commerce, and digital finance, and incubators can harness this trend.

Addressing Socio-Economic Challenges

Africa face challenges in healthcare, education, clean water, and energy.
Incubators with a focus on social enterprises play a pivotal role in supporting startups that address these issues through innovative and scalable solutions

Pan-African Trade and Collaboration

The African Continental Free Trade Area (AfCFTA) -unified market of over 1.3 billion people
Drive opportunities for businesses to scale across borders.
Incubators that help businesses navigate different African markets and access regional supply chains are in a strong position to succeed

Solidarity
Equality
Sustainability

G20
SOUTH AFRICA 2025

Solidarity
Equality
Sustainability

Gaps in Africa's Incubation and Acceleration Landscape

Gaps in Africa's Incubation and Acceleration Landscape

Fragmented Ecosystem:

- Lack of cohesive networks
- startups, investors, and research institutions.

Infrastructure Deficits:

- Lacks large-scale R&D facilities
- accessible startup lab spaces
- comprehensive infrastructure

Funding Constraints:

- Scarcity of venture capital Funds
- Very few specific to Bioeconomy.

Government Ineffectiveness:

- Bureaucratic hurdles
- Poorly managed funds
- Inadequate expertise

Critical Gaps:

- Limited access to specialised services, e.g;
  - Analytical, imaging, gene synthesis etc,
- Lack of Business/Science Interface
  - No Business Acumen
  - Bioentrepreneurship unique challenges

University Limitations:

- Academic facilities need to be faster
- more reliable and respond to commercial needs,
- creating a gap for private service platforms



Regulatory Hurdles:

- Complex and inconsistent regulatory frameworks across countries.
- Blanket approach to new areas
- Creating barriers to entry

Solidarity
Equality
Sustainability

G20
SOUTH AFRICA 2025

Solidarity
Equality
Sustainability

Comparative Analysis: Africa vs. Developed Countries

ECOSYSTEM STRUCTURE

FRAGMENTED VS. INTEGRATED

Developed world

Well-developed biotech hubs (e.g., Boston, Silicon Valley, Germany's BioValley) that integrate startups, universities, venture capitalists, and regulatory bodies.

Strong public-private partnerships encourage knowledge transfer and commercialization of research.

Dedicated innovation clusters like the UK's Golden Triangle (Oxford, Cambridge, London) facilitate biotech growth with government support and private-sector investment

The biotech ecosystem is highly fragmented, with weak links between academia, industry, government, and investors.

Few structured clusters where biotech startups, incubators, universities, and research institutions work in synergy.

Limited collaboration between stakeholders, leading to duplication of efforts and inefficiencies.

Example: Many African universities conduct biotech research, but commercializing innovations is slow due to weak technology transfer offices (TTOs) and lack of funding.

Africa

ACCESS TO INFRASTRUCTURE

LIMITED VS. ADVANCED

Developed world

State-of-the-art research labs with open-access models for startups and academic spin-offs.

Strong infrastructure for biomanufacturing, clinical trials, and advanced analytics.

Stable energy supply and access to cutting-edge technologies enable faster R&D and production.

Example: The U.S. and Germany have biotech incubators with full laboratory facilities that reduce startup costs.

Few open-access biotech labs for startups.

Limited access to high-tech research equipment like gene sequencers, bioreactors, etc,

Shortages of cold chain storage and bio-manufacturing facilities.

Many startups rely on foreign partnerships for advanced testing and trials.

Energy and internet instability in some regions hinder research and biotech production.

Example: African biotech companies often outsource critical R&D to Europe or the U.S. due to infrastructure gaps.

Africa

FUNDING & INVESTMENT

SCARCE VS. ABUNDANT

Developed world

Robust biotech venture capital ecosystem (e.g., U.S. biotech startups raised over $50 billion in VC in 2023).

Well-established angel investor networks, biotech-specific funds, and IPO opportunities.

Government grants, subsidies, and large-scale public-private partnerships ensure steady funding.

Example: In the U.S., NIH (National Institutes of Health) and BARDA (Biomedical Advanced Research and Development Authority) provide billions in research grants annually.

Few venture capital (VC) firms only one focused on biotech.

High-risk perception among investors due to long development cycles and regulatory challenges.

Over-reliance on grants and donor funding instead of sustainable private investment.

Many government funding programs are small-scale and not targeted toward deep biotech innovation.

Example: Less than 1% of total venture funding in Africa goes to biotech startups, compared to fintech and e-commerce.

Africa

Solidarity
Equality
Sustainability

REGULATORY LANDSCAPE

WEAK VS. STRONG FRAMEWORKS

Developed world

Well-established biotech regulatory frameworks (e.g., FDA in the U.S., EMA in Europe).

Clear guidelines for clinical trials, drug approvals, and genetic engineering regulations.

Strong intellectual property (IP) laws protect biotech innovations, encouraging investment.

Example: The U.S. has a standardized biotech regulatory pathway, enabling startups to scale quickly with clear compliance guidelines.

.

Inconsistent and slow regulatory approval processes across different countries.

Lack of a harmonized continental biotech policy, making it difficult for startups to scale across borders.

Bureaucratic delays in clinical trial approvals and new product certifications.

Weak IP (Intellectual Property) protections discourage foreign investment in biotech R&D.

Example: A biotech company in South Africa may face entirely different regulatory hurdles than one in Kenya or Nigeria.

Africa

MARKET ACCESS

LIMITED VS. GLOBAL

Developed world

Strong domestic and international markets for biotech products.

Trade agreements and strong global networks make it easier for companies to export biotech innovations.

Governments actively promote biotech exports and global partnerships.

Limited local demand for biotech products due to affordability and awareness issues.

Biotech markets are underdeveloped, and many startups struggle to find customers.

Export barriers:

African biotech companies face high trade restrictions and tariffs when entering international markets.

Weak regional trade agreements limit intra-Africa biotech trade.

Example: African-made vaccines often struggle to gain traction due to competition from multinational pharmaceutical companies.

Africa

TALENT & SKILLS

SHORTAGE VS. READILY AVAILABLE WORKFORCE

Developed world

Large talent pools with specialized biotech expertise.

Strong university-industry collaboration for workforce development.

Example: The U.S. has over 200 biotech-focused degree programs and multiple entrepreneurship training initiatives.

Shortage of skilled biotech professionals due to weak investment in biotech education and R&D.

Limited industry-academia collaboration, causing a mismatch between university training and industry needs.

Brain drain: Many trained African biotech professionals migrate to the U.S. or Europe for better opportunities.

Africa

INDIGENOUS KNOWLEDGE SYSTEMS (IKS) & BIOPROSPECTING

OPPORTUNITY

Developed world

Less focus on Indigenous knowledge as a source of biotech innovation.

Strong IP protections prevent biopiracy but can sometimes limit knowledge sharing.

Vast traditional knowledge on medicinal plants, agriculture, and health.

Need for stronger frameworks to protect Indigenous Knowledge Systems (IKS) from exploitation.

Few incubators focused on integrating IKS with modern biotech.

Africa

Solidarity
Equality
Sustainability

WHAT DOES AFRICA NEED TO FOCUS ON TO COMPETE?

Strengthen Biotech Ecosystem:	Develop Biotech Infrastructure:	Increase Funding:	Regulatory Reforms	Market Development	Talent Development	Protect Indigenous Knowledge
Improve collaboration between universities, government, and industry.	Invest in open-access labs, manufacturing facilities, and research hubs.	Establish biotech-focused VC funds, angel investor networks, and public-private partnerships.	Streamline approval processes and harmonize biotech policies across Africa.	Create policies that boost local demand and ease export barriers.	Expand biotech education and provide incentives to retain skilled professionals.	Implement frameworks to safeguard and commercialise traditional knowledge.

UVU Bio
Seeding Success, Cultivating Talent:

Accelerating Africa's Bioeconomy with Entrepreneurial Innovation, Skills Development, and Access to World Class Labs and Research Services


Rwanda Bioeconomy Hub
Bioeconomy Skills Centre
South Africa Training and Innovation Centre

Tackling Startup Hurdles: How UVU Bio Bridges the Gap

We provide **state-of-the-art biotech labs**, **funding networks**, **expert individualized mentorship**, **comprehensive training**, **R&D support**, and **collaboration opportunities** to drive innovation and growth in startups.

Networks, Collaborations and Partnerships

Limited Access to Infrastructure & Facilities

Limited Access to Funding

Shortage of Skilled Talent

High R&D costs

Minimal Collaboration & Networking Opportunities

Regulatory Requirements

Funding readiness

R&D services for product refinement

Specialised Mentorship

Open Access Lab Facilities

Bio-entrepreneurship Courses

Ecosystem Access

UVU BIO

Individualised business and technical support across the entrepreneur journey

G20
SOUTH AFRICA 2025

Solidarity
Equality
Sustainability

Thank you

Dheepak Maharajh
Dheepak@uvubio.com